HIGHLIGHTS
- who: Mieczysu0142aw Dutka and colleagues from the Department of Biochemistry and Molecular Biology, Faculty of Health Sciences, University of Bielsko-Biala, Bielsko-Biau0142a, Poland have published the article: SGLT-2 Inhibitors in Cancer Treatmentu2014Mechanisms of Action and Emerging New Perspectives, in the Journal: Cancers 2022, 14, 5811. of /2022/
- what: This review showed that SGLT-2 inhibitor use is not associated with an increased risk of any cancer which was confirmed when SGLT-2 inhibitors were compared with both a placebo and with active comparators (glimepiride, metformin, sitagliptin, saxagliptin, linagliptin, insulin). Studies were conducted to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.